HPV DNA and XXXX alterations in @entity189 .

@entity5 @entity957 @entity189 @entity876 @entity1799
We have examined a series of 37 @entity957 for the presence of HPV 6/11, 16, and 18 DNA by polymerase chain reaction (PCR)/Southern blotting and for @entity876 alterations by immunohistochemistry and mutation screening with temperature gradient gel electrophoresis (TGGE). HPV sequences were found in a total of 26 of 37 @entity5 (70.3%), most frequently @entity1799 (20/37) followed by HPV 18 (11/37). Double infections with @entity1799 and 18 were present in 5 @entity5 . @entity876 accumulation was detectable immunohistochemically in 21 of 37 @entity189 (56.8%). There were remarkable differences in the distribution of immunoreactive @entity5 cells in relation to the @entity5 grade. A mutation screening for @entity876 by TGGE, directed to the amplified exons 5-8, revealed @entity876 mutations in 14 of 37 @entity189 (37.8%). Mutations in two different exons were present in 3 @entity5 , 11 @entity5 being hit once. Exon 7 was mutated in 6 @entity189 , exons 5 and 8 in 4 cases, and exon 6 in 3 cases. When grouping the @entity5 with @entity876 mutation according to their HPV state, HPV-positive cases showed slightly more mutations (11/26) than HPV-negative cases (3/11). Only 5 of 37 @entity189 (13.5%) contained neither HPV DNA nor @entity876 alterations. Our results indicate that high-risk HPV and @entity876 mutations frequently coexist in @entity189 , in @entity5 , @entity189 of the cervix uteri. This may reflect different pathways in carcinogenesis in squamous cell epithelium from different sites.
